Gender characteristics of non-alcoholic fatty liver disease course

Abstract

Objective. To study the clinical picture, functional indicators of the liver, lipid spectrum, proinflammatory cytokine levels and epithelial dysfunction markers in patients with non-alcoholic fatty liver disease (NAFLD) so as to detect gender differences.

Materials and methods. Fifty-two persons with a mean age of 43.0 ± 11.1 years including 17 men (33 %) and 35 women (67 %), who suffered from NAFLD against the background of obesity were examined. The comparison group enclosed 30 practically healthy persons aged 42.3 ± 7.0 years, who had no liver pathology and obesity. The laboratory study included the assessment of functional liver tests, lipid spectrum, proinflammatory cytokine levels and epithelial dysfunction markers.Steatosis of the liver was determined with the method of ultrasonic investigation.

Results. In the examined group with NAFLD, there prevailed women (67 %). The structure of complains and concomitant pathology had no marked gender differences. The USI showed the symptoms of liver steatosis in all the patients. Among men and women with NAFLD, normal transaminase levels, cholestasis syndrome, more expressed in men, similar disorders of blood lipid spectrum were registered. The proinflammatory cytokine concentrations in the blood serum of female patients with steatosis were significantly higher than in the comparison group and among males with NAFLD. The disturbance of the endothelial angiogenic function in the form of increased vasculoendothelial growth factor concentration more pronounced in men than in steatosis women was detected (р = 0.031).

Conclusions. Among women with NAFLD, slightly expressed cholestasis syndrome, dyslipidemia, signs of systemic inflammation with increased proinflammatory cytokine concentration and disturbance of angiogenic function of endothelium were registered. In men with liver steatosis, there was identified cholestasis syndrome, dyslipidemia, and angiogenic dysfunction of endothelium, more marked than in women.  

Keywords

non-alcoholic fatty liver disease / gender differences / dyslipidemia / cytokines / endothelial dysfunction

References

[1] Vinnitskaya E.V., Sandler Yu.G., Bordin D.S. A new paradigm of non-alcoholic fatty liver disease: phenotypic diversity of metabolically associated fatty liver disease. NEffektivnaya farmakoterapiya 2020; 16 (24): 54–63 (in Russian).

[2] Винницкая Е.В., Сандлер Ю.Г., Бордин Д.С. Новая парадигма неалкогольной жировой болезни печени: фенотипическое многообразие метаболически ассоциированной жировой болезни печени. Эффективная фармакотерапия 2020; 16 (24):

[3] Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7: 851–861. DOI: 10.1016/S2468-1253(22)00165-0.

[4] 54–63.

[5] Livzan M.A., Syrovenko M.I., Krolevets T.S. Non-alcoholic fatty liver disease and women's health. RMZh. Meditsinskoe obozrenie 2023; 7 (5): 310–317. DOI: 10.32364/2587-6821-2023-7-5-9 (in Rus-sian).

[6] Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and metaanalysis. Lancet Gastroenterol Hepatol 2022; 7: 851–861. DOI: 10.1016/S2468-1253(22)00165-0.

[7] Arshad T., Golabi P., Paik J. et al. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun. 2019; 3 (1): 74–83. DOI: 10.1002/hep4.1285.

[8] Ливзан М.А., Сыровенко М.И., Кролевец Т.С. Неалкогольная жировая болезнь печени и женское здоровье. РМЖ. Медицинское обозрение 2023; 7 (5): 310–317. DOI: 10.32364/2587-6821-2023-7-5-9.

[9] Paik J.M., Henry L., De Avila L. et al. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019; 3 (11): 1459–1471. DOI: 10.1002/hep4.1419.

[10] Arshad T., Golabi P., Paik J. et al. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun. 2019; 3 (1): 74–83. DOI: 10.1002/hep4.1285.

[11] Wang Z., Xu M., Hu Z. et al. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol. 2014; 26: 1015–1021. DOI: 10.1097/MEG.0000000000000151.

[12] Paik J.M., Henry L., De Avila L. et al. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019; 3 (11): 1459–1471. DOI: 10.1002/hep4.1419.

[13] Singh D.K., Sakhuja P., Malhotra V. et al. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Dig Dis Sci. 2008; 53: 1967–1976. DOI: 10.1007/s10620-007-0074-0.

[14] Wang Z., Xu M., Hu Z. et al. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol. 2014; 26: 1015–1021. DOI: 10.1097/

[15] Bambha K., Belt P., Abraham M. et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012; 55: 769–780. DOI: 10.1002/hep.24726.

[16] MEG.0000000000000151.

[17] Tapper E.B., Krajewski K., Lai M. et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014; 2: 276–280. DOI: 10.1093/gastro/gou034.

[18] Singh D.K., Sakhuja P., Malhotra V. et al. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Dig Dis Sci. 2008; 53: 1967–1976. DOI: 10.1007/s10620-007-0074-0.

[19] Ballestri S., Nascimbeni F., Baldelli E. et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017; 34 (6): 1291–1326. DOI: 10.1007/s12325-017-0556-1.

[20] Bambha K., Belt P., Abraham M. et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55: 769–780. DOI: 10.1002/hep.24726.

[21] Maevskaya, M.V., Kotovskaya Yu.V., Ivashkin V.T. i dr. National Consensus for physicians on the management of adult patients with non-alcoholic fatty liver disease and its main comorbid conditions. Terapevticheskiy arkhiv 2022; 94 (2): 216–253 (in Russian).

[22] Tapper E.B., Krajewski K., Lai M. et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014; 2: 276–280. DOI: 10.1093/gastro/gou034.

[23] Bodryagina E.S., Akberova D.R., Mukha-metova D.D., Abdulganieva D.I., Odintsova A.Kh. Gender differences and clinical features of liver and biliary tract diseases. Prakticheskaya meditsina 2021; 19 (4): 93–98. DOI: 10.32000/2072-1757-2021-4-93-98 (in Russian).

[24] Ballestri S., Nascimbeni F., Baldelli E. et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017; 34 (6): 1291–1326. DOI: 10.1007/s12325-017-0556-1.

[25] Younossi Z.M., Anstee Q.M., Marietti М. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15 (1): 11–20.

[26] Маевская, М.В., Котовская Ю.В., Ивашкин В.Т. и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив 2022; 94 (2): 216–253.

[27] Krolevets T.S., Livzan M.A. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Eksperimental'naya i klinicheskaya gastroenterologiya 2018; 7 (155): 43–51 (in Russian).

[28] Бодрягина Е.С., Акберова Д.Р., Мухаметова Д.Д., Абдулганиева Д.И., Одинцова А.Х. Гендерные различия и клинические особенности заболеваний печени и желчевыводящих путей. Практическая медицина 2021; 19 (4): 93–98. DOI: 10.32000/2072-1757-2021-4-93-98

[29] Lazebnik L.B., Golovanova U.V., Turkina S.V. Non-alcoholic fatty liver disease in adults: clinic, diagnosis, treatment. Recommendations for therapists, the third version. Eksperimental'naya i klinich-eskaya gastroenterologiya 2021; 1 (1): 4–52 (in Russian).

[30] Younossi Z.M., Anstee Q.M., Marietti М. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15 (1): 11–20.

[31] Haukeland J.W., Damas J.K., Konopski Z. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44: 1167–1174. DOI: 10.1016/j.jhep.2006.02.011.

[32] Кролевец Т.С., Ливзан М.А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология 2018; 7 (155): 43–51.

[33] Turola E., Petta S., Vanni E. et al. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech. 2015; 8: 1037–1046. DOI: 10.1242/dmm.019950.

[34] Лазебник Л.Б., Голованова У.В., Турки-на С.В. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология 2021; 1 (1): 4–52.

[35] Petrishchev, N.N., Vasina L.V., Vlasov T.D. Endothelial dysfunction and its main markers. Regional'noe krovoobrashchenie i mikrotsirkulyatsiya 2017; 1 (61): 4–15 (in Russian).

[36] Haukeland J.W., Damas J.K., Konopski Z. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44: 1167–1174. DOI: 10.1016/j.jhep.2006.02.011.

[37] Awards A., Bangar M., Menezes C. et al. Gender differences in non-alcoholic fatty liver disease. Eurasian J Hepatogastroen-terologist 2022; 12: 19–25. DOI: 10.5005/jp-journals-10018-1370

[38] Turola E., Petta S., Vanni E. et al. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech. 2015; 8: 1037–1046. DOI: 10.1242/dmm.019950.

[39] Suzuki A., Diehl A.M. Nonalcoholic stea-tohepatitis. Annu Rev Med. 2017; 68: 85–98. DOI: 10.1146/annurev-med-051215-031109.

[40] Петрищев, Н.Н., Васина Л.В., Власов Т.Д. Эндотелиальная дисфункция и ее основные маркеры. Региональное кровообращение и микроциркуляция 2017; 1 (61): 4–15.

[41] Tobari M., Hashimoto E., Taniai M. et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign. J Gastroenterol Hepatol. 2019; 34: 1404–1410. DOI: 10.1111/jgh.14585.

[42] Awards A., Bangar M., Menezes C. et al. Gender differences in non-alcoholic fatty liver disease. Eurasian J Hepatogastroenterologist. 2022; 12: 19–25. DOI: 10.5005/jp-journals-10018-1370

[43] Yang J.D., Abdelmalek M.F., Pang H. et al. Gender andmenopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59: 1406–1414. DOI: 10.1002/hep.26761.

[44] Suzuki A., Diehl A.M. Nonalcoholic steatohepatitis. Annu Rev Med. 2017; 68: 85–98. DOI: 10.1146/annurev-med-051215-031109.

[45] Bulatova I.A., Shevlyukova T.P., Gulyaeva I.L., Sobol' A.A., Paducheva S.V. Features of the course of non-alcoholic liver steatosis in women of reproductive age and menopause. Meditsinskiy sovet 2022; 15:

[46] Tobari M., Hashimoto E., Taniai M. et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign. J Gastroenterol Hepatol. 2019; 34: 1404–1410. DOI: 10.1111/jgh.14585.

[47] 62–69. DOI: 10.21518/2079-701X-2022-16-15-62-69 (in Russian).

[48] Yang J.D., Abdelmalek M.F., Pang H. et al. Gender andmenopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59: 1406–1414. DOI: 10.1002/hep.26761.

[49] Булатова И.А., Шевлюкова Т.П., Гуляева И.Л., Соболь А.А., Падучева С.В. Особенности течения неалкогольного стеатоза печени у женщин репродуктивного возраста и в менопаузе. Медицинский совет 2022; 15: 62–69. DOI: 10.21518/2079-701X-2022-16-15-62-69

RIGHTS & PERMISSIONS

Eco-Vector